Menu
Back to Journals » Biologics: Targets and Therapy » Volume 1 » Issue 2
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 5,469 | Dovepress* | 5,469+ | 2,142 | 7,611 | |
| Totals | 5,469 | 2,142 | 7,611 | ||
|
*Since 15 November 2007 +Since July 2016 |
|||||
View citations on Google Scholar